GOLD Treatment Recommendations for COPD Now Include Use of Endobronchial Valves to Treat Patients with Emphysema
Redwood City, Calif. – November 18, 2016 – The Global Initiative for Chronic Obstructive Lung Disease (GOLD) issued a substantial revision to its COPD management recommendations that now includes bronchoscopic lung volume reduction with endobronchial valves as a treatment option for patients with…
Pulmonx Completes Enrollment in U.S. Pivotal Trial of Zephyr®Endobronchial Valve
Redwood City, Calif. – October 5, 2016 – Pulmonx, a leader in interventional pulmonology, today announced completion of enrollment in its pivotal IDE study – the LIBERATE Trial – a randomized, controlled, multi-center study of the Zephyr® Endobronchial Valve (EBV) in patients with severe emphysema,…
New Study Demonstrates Benefits of Pulmonx Zephyr®Endobronchial Valve in Patients with Homogeneous Emphysema
Results Published in American Journal of Respiratory and Critical Care Medicine Show Meaningful Improvements in Patient Lung Function, Exercise Tolerance and Quality of Life
New StratX Lung Analysis Platform from Pulmonx Enables Confident and Rapid Patient Selection for Zephyr® Endobronchial Valve Treatment
Cloud-Based Quantitative Computed Tomography (QCT) Analysis Service is Now Commercially Available
STELVIO Trial Shows Sustained Benefits for Emphysema Patients One Year After Treatment with Zephyr® Endobronchial Valves
Redwood City, Calif. – May 18, 2016 – Pulmonx®, a leader in interventional pulmonology, today announced positive one year results from the groundbreaking STELVIO trial. The STELVIO trial is the first randomized controlled study of Zephyr® Endobronchial Valves (EBV) in severe emphysema patients…